Mobile

A Study of ARN-810 (GDC-0810) Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-004852-77

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase Ia: To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) and assess the safety of single agent GDC-0810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer Phase IIa: To determine the anti-tumor activity of single agent of GDC0810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer

Critère d'inclusion

  • Patients with locally advanced or metastatic estrogen receptor (ER) positive breast cancer

Liens